- Markets
- Chemicals
- GENPHARMA
GENPHARMA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Genpharmasec Enters Into Agreement With Amneal Healthcare
Dec 10 (Reuters) - Genpharmasec Ltd GENP.BO:
ENTERS INTO AGREEMENT WITH AMNEAL HEALTHCARE
APPOINTMENT OF CO AS NONEXCLUSIVE SUPPER STOCKIST
AHPL TO PROVIDE CO WITH MINIMUM ANNUAL SALES COMMITMENT OF ABOUT 600 MILLION RUPEES
Source text: ID:nBSE1W1cxf
Further company coverage: GENP.BO
(([email protected];;))
Dec 10 (Reuters) - Genpharmasec Ltd GENP.BO:
ENTERS INTO AGREEMENT WITH AMNEAL HEALTHCARE
APPOINTMENT OF CO AS NONEXCLUSIVE SUPPER STOCKIST
AHPL TO PROVIDE CO WITH MINIMUM ANNUAL SALES COMMITMENT OF ABOUT 600 MILLION RUPEES
Source text: ID:nBSE1W1cxf
Further company coverage: GENP.BO
(([email protected];;))
Genpharmasec Says Executed Definitive Agreement With Derren Healthcare
Sept 20 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC EXECUTED DEFINITIVE AGREEMENT WITH DERREN HEALTHCARE AND ITS SHAREHOLDERS TO ACQUIRE 70% STAKE
OVERALL PURCHASE CONSIDERATION FOR ACQUISITION OF 70% OF DHPL IS 330 MILLION RUPEES
Source text for Eikon: ID:nBSE6jZDYH
Further company coverage: GENP.BO
(([email protected];;))
Sept 20 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC EXECUTED DEFINITIVE AGREEMENT WITH DERREN HEALTHCARE AND ITS SHAREHOLDERS TO ACQUIRE 70% STAKE
OVERALL PURCHASE CONSIDERATION FOR ACQUISITION OF 70% OF DHPL IS 330 MILLION RUPEES
Source text for Eikon: ID:nBSE6jZDYH
Further company coverage: GENP.BO
(([email protected];;))
Genpharmasec Approved Issuance Of Shares Of An Issue Size Upto 490 Million Rupees
June 5 (Reuters) - Genpharmasec Ltd GENP.BO:
APPROVED ISSUANCE OF SHARES OF AN ISSUE SIZE UPTO 490 MILLION RUPEES
APPROVED ISSUANCE OF EQUITY SHARES ON RIGHTS BASIS
Source text for Eikon: ID:nBSEc5xnSP
Further company coverage: GENP.BO
(([email protected];))
June 5 (Reuters) - Genpharmasec Ltd GENP.BO:
APPROVED ISSUANCE OF SHARES OF AN ISSUE SIZE UPTO 490 MILLION RUPEES
APPROVED ISSUANCE OF EQUITY SHARES ON RIGHTS BASIS
Source text for Eikon: ID:nBSEc5xnSP
Further company coverage: GENP.BO
(([email protected];))
Genpharmasec To Consider Proposal For Raising Of Funds
May 30 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC LTD - TO CONSIDER PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE4csx5M
Further company coverage: GENP.BO
(([email protected];))
May 30 (Reuters) - Genpharmasec Ltd GENP.BO:
GENPHARMASEC LTD - TO CONSIDER PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE4csx5M
Further company coverage: GENP.BO
(([email protected];))
Events:
Rights
Split
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Genpharmasec do?
Adi Rasayan Ltd is a company that specializes in the manufacturing and trading of organic and inorganic chemicals, dyes, and pigments.
Who are the competitors of Genpharmasec?
Genpharmasec major competitors are Ishan Dyes and Chem., Metroglobal, Aksharchem (I), Seya Industries, Chemcrux Enterprises, Vipul Organics, Poddar Pigments. Market Cap of Genpharmasec is ₹128 Crs. While the median market cap of its peers are ₹191 Crs.
Is Genpharmasec financially stable compared to its competitors?
Genpharmasec seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Genpharmasec pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Genpharmasec latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Genpharmasec allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Genpharmasec balance sheet?
Balance sheet of Genpharmasec is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Genpharmasec improving?
The profit is oscillating. The profit of Genpharmasec is ₹1.5 Crs for TTM, -₹0.13 Crs for Mar 2024 and ₹1.12 Crs for Mar 2023.
Is the debt of Genpharmasec increasing or decreasing?
Yes, The debt of Genpharmasec is increasing. Latest debt of Genpharmasec is -₹0.61 Crs as of Sep-24. This is greater than Mar-24 when it was -₹34.4 Crs.
Is Genpharmasec stock expensive?
Genpharmasec is not expensive. Latest PE of Genpharmasec is 85.1, while 3 year average PE is 147. Also latest EV/EBITDA of Genpharmasec is 123 while 3yr average is 248.
Has the share price of Genpharmasec grown faster than its competition?
Genpharmasec has given lower returns compared to its competitors. Genpharmasec has grown at ~-1.78% over the last 8yrs while peers have grown at a median rate of 1.78%
Is the promoter bullish about Genpharmasec?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Genpharmasec is 29.98% and last quarter promoter holding is 29.98%.
Are mutual funds buying/selling Genpharmasec?
There is Insufficient data to gauge this.